Frontlight ResearchEarly access
CompletedNo phase
Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS
Key facts
- Who runs it
- Mst.Sumyara Khatun
- Where
- Bangladesh1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 12 Aug 2024
- Ended
- 20 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pioglitazone 30 Mg Oral Tablet
- metformin 500 mg thrice daily
- Record updated
- 16 March 2026
Who can take part
- Age
- 18 years to 35 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Diagnosed case of PCOS patients according to Rotterdam criteria
- HOMA-IR >2 (Hydrie et al., 2012)
- Age: 18-35 years
- BMI: 18.5 -27.5 kg/m²
Who cannot take part
- Any medication in the last three months which would affect insulin resistance (metformin, oral contraceptive pill)
- Presence of any endocrine disorder (hyperthyroidism, hypothyroidism, cushing syndrome, congenital adrenal hyperplasia, hyperprolactinaemia, diabetes mellitus)
- Presence of any medical comorbidity (renal, hepatic and cardiovascular disease)
- Any contraindications to Pioglitazone (Patients with a known hypersensitivity to pioglitazone or any of its components, Diabetic ketoacidosis or type 1 diabetes) or Metformin (severe chronic diseases e.g. hepatic, renal and cardiac failure or acute complications of diabetes e.g. ketoacidosis and hyperosmolar state)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Women with PCOS with HOMA-IR >2 fulfilling inclusion and exclusion criteria are randomly allocated into two groups: group A: pioglitazone 30 mg once daily and group B: Metformin 500 thrice daily for 3 months.Each group contains 30 participants. Outcome variables are measured after 3 months.
The 2 groups in the trial
- Experimental armTreatment being tested
pioglitazone 30 mg once daily
Treatment: Pioglitazone 30 Mg Oral Tablet and metformin 500 mg thrice daily
- Comparator armExisting treatment, for comparison
metformin 500mg thrice daily for 3 months
Treatment: Pioglitazone 30 Mg Oral Tablet and metformin 500 mg thrice daily
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Pioglitazone on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS in Comparison to Metformin
- Record updated
- 16 March 2026